covid-19

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.

Masavibart (ZRC3308-A7), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, demonstrates strong binding affinity for a distinct non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When paired in a 1:1 ratio with ZRC3308-B10, Masavibart is efficacious in preventing COVID-19, particularly in its early stages before the onset of severe symptoms [1].

Nepuvibart (ZRC3308-B10), an IgG1 type anti-SARS-CoV-2 monoclonal antibody, exhibits strong binding affinity to a distinct non-competing epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When combined in a 1:1 ratio with ZRC3308-A7, Nepuvibart is effective in preventing COVID-19 and in treating the early stages of the disease before it progresses to severe illness [1].

Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1].

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].

Foralumab (NI-0401) is an orally available human anti-CD3 monoclonal antibody that downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells from COVID-19 subjects for the study of COVID-19 infection.

Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.

Daxdilimab, an anti-ILT7 monoclonal antibody, targets the ILT7 cell surface molecule exclusive to pDC dendritic cells. It shows potential for treating acute lung injury (ALI) in COVID-19 infected patients, as indicated in research [1] [2].

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Sotrovimab (VIR 7831) is a monoclonal antibody against the SARS-CoV-2 virus that causes COVID-19. It has antiviral activity, induces serum neutralization of BQ.1 and antibody-dependent cytotoxicity, and may be used to study viral infections.

Casirivimab (REGN10933), a human monoclonal antibody targeting the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging variants. When combined with Imdevimab, it significantly lowers viral load and enhances disease outcomes [1].

Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].

Regdanvimab (CT-P59) is a humanized antibody targeting the spike protein of SARS-CoV-2, with antiviral activity. It prevents viral entry by blocking interactions with ACE2, used in studies of COVID-19 infection.

Amubarvimab (BRII-196) is a humanized recombinant antibody targeting the spike protein of SARS-CoV-2, with antiviral activity, used in studies of COVID-19 infection.

Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.

Cilgavimab (AZD-1061) is a humanized monoclonal antibody targeting the spike protein of SARS-CoV-2, used in studies of COVID-19 infection.

Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cancer activity and can be used to study ossifying fibrous dysplasia (FOP) and cancer.

Lomtegovimab (BI 767551), a humanized monoclonal antibody targeting the SARS-CoV-2 spike glycoprotein, exhibits antiviral efficacy by binding to and neutralizing the virus. This compound holds potential for COVID-19 research [1] [2].

Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activity, regulates the biological function of GM-CSF by blocking the interaction between GM-CSF and its cell surface receptors, and can be used in studies to treat severe COVID-19 pneumonia.

Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19 and has potential applications in treating ARDS related to COVID-19, subject to ongoing research [1].

Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.

Efmarodocokin alfa, a fusion protein combining human IL-22 with the IgG4 crystallizable fragment, activates IL-22 signaling. This compound has potential applications in the study of severe COVID-19 pneumonia [1].